MRTX News and Press, Mirati Therapeutics Inc. From 11/01/21

Regional banks provided a significant bright spot on a generally lackluster session on Monday. A more than 20% gain in Silvergate Capital (NYSE:SI) led the sector higher, as investors focused on the company's cryptocurrency operations, part of a diversification that has marked the space recen...

Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021 PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, ...

Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...

The Chief Operating Officer, Daniel Faga, and Chief Medical Officer, Joseph Leveque, of Mirati Therapeutics (NASDAQ:MRTX) have departed the company, effective today. Faga also served as Mirati's principal financial officer. Vickie Reed, the company's chief accounting officer, is taking over a...

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer PR Newswire SAN DIEGO , Oct. 7, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clini...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer PR Newswire SAN DIEGO , Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASD...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , Sept. 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in connection w...

The major U.S. equity averages saw significant weakness in Monday's pre-market trading, led lower by a drop in Chinese stocks. JD.com, Inc. (NASDAQ:JD), Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU) were among the high-profile names losing ground. Other stocks fell on company-specific headlines...

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors PR Newswire SAN DIEGO , Sept. 20, 2021 /PRNews...